Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 8/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.47 |
| ▸ | KRAS | P01116 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | BCL2L11 | O43521 | 1/20 | 0.38 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3780018 | 0.81 | MTNR1B (0.48) | MTNR1BMTNR1AKRASCYP3A4TSHR | |
| SCHEMBL24916019 | 0.79 | CYP1A1 (0.34) | MTNR1BMTNR1AMEN1CYP1A2CYP3A4 | |
| SCHEMBL10199247 | 0.78 | GABRA1 (0.36) | CYP1A2CYP3A4BCL2L11BCL2L1EGFR | |
| SCHEMBL18905193 | 0.78 | CYP1A2 (0.47) | CYP1A2CYP3A4KMT2ABCL2L11BCL2L1 | |
| SCHEMBL22766493 | 0.78 | MTNR1B (0.50) | MTNR1BMTNR1ACYP1A2CYP3A4CYP2C19 | |
| SCHEMBL27947745 | 0.78 | MTNR1B (0.50) | MTNR1BMTNR1AMEN1CYP1A2CYP3A4 | |
| SCHEMBL24915594 | 0.77 | MTNR1B (0.33) | MTNR1BMTNR1AMEN1CYP1A2CYP3A4 | |
| SCHEMBL425260 | 0.77 | MTNR1B (0.49) | MTNR1BMTNR1AMEN1CYP1A2CYP3A4 | |
| SCHEMBL3249749 | 0.77 | MTNR1B (0.52) | MTNR1BMTNR1AMEN1KMT2AEGFR | |
| SCHEMBL5265681 | 0.77 | MTNR1B (0.51) | MTNR1BMTNR1AMEN1CYP3A4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CONTINEUM THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| WO-2020047208-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219947-A1 | INHIBITORS OF AV ß6 INTEGRIN | ITGB6, ITGA6, GP6 | MTNR1B 2716/4885MTNR1A 4004/4885KRAS 1692/4885 |
| US-20210155629-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | CHRM1, CHRM2, CHRM5 | MTNR1B 67/4885MTNR1A 50/4885KRAS 4404/4885 |
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | MTNR1B 3677/4885MTNR1A 3776/4885KRAS 1236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.